Lv11
40 积分 2021-10-24 加入
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus
3个月前
已完结
Structural Dynamics of Insulin Receptor and Transmembrane Signaling
3个月前
已完结
Claudin 18.2 as a novel therapeutic target
3个月前
已完结
Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
3个月前
已完结
Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial
11个月前
已关闭
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
11个月前
已完结
Discovery of the RANKL/RANK/OPG system
11个月前
已完结
Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study
1年前
已完结
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
1年前
已完结
Bone-Muscle Mutual Interactions
1年前
已完结
皖公网安备34019202002308
